Ixmyelocel-T, an expanded multicellular therapy, contains a unique population of M2-like macrophages by Kelly J Ledford et al.
Ledford et al. Stem Cell Research & Therapy 2013, 4:134
http://stemcellres.com/content/4/6/134RESEARCH Open AccessIxmyelocel-T, an expanded multicellular therapy,
contains a unique population of M2-like
macrophages
Kelly J Ledford, Frank Zeigler and Ronnda L Bartel*Abstract
Introduction: M2 macrophages promote tissue repair and regeneration through various mechanisms including
immunomodulation and scavenging of tissue debris. Delivering increased numbers of these cells to ischemic
tissues may limit tissue injury and promote repair. Ixmyelocel-T is an expanded, autologous multicellular therapy
cultured from bone-marrow mononuclear cells (BMMNCs). The purpose of this study was to characterize further a
unique expanded population of M2-like macrophages, generated in ixmyelocel-T therapy.
Methods: Approximately 50 ml of whole bone marrow was obtained from healthy donors and shipped overnight.
BMMNCs were produced by using density-gradient separation and cultured for approximately 12 days to generate
ixmyelocel-T. CD14+ cells were isolated from ixmyelocel-T with positive selection for analysis. Cell-surface phenotype was
examined with flow cytometry and immunofluorescence, and expression of cytokines and chemokines was analyzed
with enzyme-linked immunosorbent assay (ELISA). Quantitative real-time PCR was used to analyze expression of genes
in BMMNCs, ixmyelocel-T, the CD14+ population from ixmyelocel-T, and M1 and M2 macrophages. Ixmyelocel-T was
cultured with apoptotic BMMNCs, and then visualized under fluorescence microscopy to assess efferocytosis.
Results: Macrophages in ixmyelocel-T therapy expressed surface markers of M2 macrophages, CD206, and CD163.
These cells were also found to express several M2 markers, and few to no M1 markers. After stimulation with
lipopolysaccharide (LPS), they showed minimal secretion of the proinflammatory cytokines interleukin-12 (IL-12)
and tumor necrosis factor alpha (TNF-α) compared with M1 and M2 macrophages. Ixmyelocel-T macrophages
efficiently ingested apoptotic BMMNCs.
Conclusions: Ixmyelocel-T therapy contains a unique population of M2-like macrophages that are characterized by
expression of M2 markers, decreased secretion of proinflammatory cytokines after inflammatory stimuli, and efficient
removal of apoptotic cells. This subpopulation of cells may have a potential role in tissue repair and regeneration.Introduction
Macrophages are a diverse population of cells that adapt
and respond to a variety of signals, including cytokines
and microbial products [1]. Macrophages can be classified
based on their functional phenotypes; M1 macrophages are
classically activated by proinflammatory cytokines such
as gamma interferon (IFN-ɣ) and are T-helper 1 (Th1)
associated, whereas M2 macrophages are alternatively
activated by cytokines such as IL-4 and IL-13, and are
T-helper 2 (Th2) associated [2]. Both in vitro and in vivo
studies have demonstrated that M1 macrophages have an* Correspondence: rbartel@aastrom.com
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reproduction in any medium, provided the orinflammatory phenotype that corresponds with the early
phases of tissue injury [1], whereas M2 macrophages have
an antiinflammatory and tissue-remodeling phenotype
corresponding with the late phases of tissue injury [1,3-8].
M2 macrophages help promote clearance of inflammatory
cells and the return of tissue homeostasis [7]. Recently, it
has become apparent that these macrophage classifications
are extremes of a wide spectrum of possible macrophage
phenotypes [8-10].
Several diseases are associated with a defect or alteration
in macrophage function [5,6,11]. M2 macrophages are
characterized as immunosuppressive and reparative, and
have been implicated in stable areas of atherosclerotic
lesions, myocardial infarction healing, and skeletal musclel Ltd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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macrophages are differentially activated during cardiac
remodeling after myocardial infarction, with M2 macro-
phages being involved in the reparative phase [11,12,14].
Studies have also shown that atherosclerotic lesions are
characterized by the presence of proinflammatory M1
macrophages that fail to switch to an antiinflammatory and
reparative phenotype, thus promoting disease progression
[5,15-17]. Therefore, increasing the proportion of M2
macrophages in such disease states could be used to limit
tissue injury and promote repair.
Ixmyelocel-T is an expanded, autologous multicellular
therapy containing a mixture of cell types cultured from
BMMNCs [18-20]. Recent clinical trials evaluating ixmye-
locel-T therapy in the treatment of dilated cardiomyopathy
and severe peripheral artery disease have shown clinical
promise [19,21,22]. Ixmyelocel-T contains a mixture of
cells; the process used to generate this cell therapy expands
both the CD90+ mesenchymal stromal cells (MSCs) and
CD14+ macrophages, while retaining many of the CD45+
cells found in the bone marrow, because the process does
not use any purification or enrichment steps, other than
phenotypic expansion. The MSCs have been previously
characterized both in vitro and in vivo [18,20]. Although
early development of ixmyelocel-T was focused on bone-
regeneration studies due to the more obvious expansion
of the MSCs which were extremely rare in bone marrow,
an initial characterization of the CD14+ hematopoietic
cells [20], demonstrated the simultaneous expansion of
macrophages, which were primarily responsible for the
secretion of high levels of IL-10 and IL-1a receptor antag-
onist, and were therefore consistent with these macro-
phages being M2-like.
The purpose of this study was to further characterize
ixmyelocel-T macrophages, and determine more precisely
their phenotype. The population of macrophages generated
in ixmyelocel-T, may be beneficial in the treatment of
diseases where tissue remodeling and immunomodulation
are key components of successful clinical outcomes. Ixmye-
locel-T macrophages are characterized as M2-like with
minimal secretion of pro-inflammatory cytokines after
inflammatory challenge, as well as efficient removal of
apoptotic cells (efferocytosis). Additionally, this data pro-
vides evidence that ixmyelocel-T contains a unique M2-
like population of macrophages when compared to in vitro
generated M1 and M2 macrophages.
Methods
Cell culture
For the generation of ixmyelocel-T commercially available
bone marrow aspirates (Lonza, MD, USA) were obtained
from healthy donors under informed consent. A small
volume (~50 mL) of whole bone marrow was obtained
through needle aspiration of the posterior iliac crest, andstored in heparinized tubes during shipment at ambient
temperature to a central processing facility. The mono-
nuclear cell fraction was obtained via an automated,
closed-system, Ficoll-based density gradient centrifugation
separation process. The isolated mononuclear cells were
then transferred to a sterile, single-use cell bioreactor
cassette [20,23]. This proprietary system controlled tem-
perature, culture medium exchange, and gas exchange
during the culture period. After approximately 12 days,
the cells were washed and harvested from the cassette by a
multistep, automated process, and ready for experimental
study. For the generation of M1 and M2 macrophages,
human peripheral blood monocytes from healthy donors
were purchased (AllCells LLC., Alameda, USA). The cells
were polarized into M1 and M2 macrophages using estab-
lished protocols [24,25]. Briefly, monocytes were differ-
entiated into macrophages by incubation with 100 ng/
mL M-CSF (R&D Systems, Minneapolis, MN, USA) in
RPMI-1640 (Invitrogen) supplemented with 20% FBS
(Invitrogen) for 7 days. The media was then removed
and the macrophages were then polarized with 10 pg/mL
LPS plus 20 ng/mL interferon gamma (IFN-ɣ) for M1
polarization, or 20 ng/mL IL-4 for M2 polarization (R&D
Systems, Minneapolis, MN, USA) in RPMI-1640 with 5%
FBS for 18 hours.CD14+ cell purification
CD14+ cells were isolated from ixmyelocel-T by positive
selection using MACS beads (Miltenyi Biotec, Bergisch
Gladbach, Germany) as per the manufacturer’s instructions.
After positive selection, the CD14+ ixmyelocel-T mac-
rophages were transferred to 6-well culture plates for
subsequent experiments. Re-analyses of the selected cells
by flow cytometry indicated a relatively pure preparation
(approximately >90%).Flow cytometry
For cell surface staining, erythrocytes were lysed with lysing
solution for 10 minutes (Becton Dickinson, Sad Jose, CA).
Fc receptors were blocked with Fc receptor blocking agent
(Miltenyi Biotech, Auburn, CA, USA) for 15 minutes at
4°C. Cells were then incubated with surface receptor
antibodies for 15 minutes at 4°C, and then washed with
phosphate buffered saline (PBS). Cell surface staining
was analyzed using the Gallios flow cytometer (Beckman
Coulter, Brea, CA, USA). Kaluza software (Beckman
Coulter) was used to analyze the acquired data. The follow-
ing antibodies were used for the analyses: anti-CD14 FITC,
anti-CD14 APC, anti-CD206 PE, anti-CD16 ECD, anti-
HLA-DR ECD and Annexin V FITC (Beckman Coulter),
anti-CD163 APC and anti-CD163 PerCP5.5 (BioLegend,
San Diego, CA, USA), and anti-MerTK (R&D Systems).
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To visualize alternatively activated macrophages in ixmye-
locel-T, cells were seeded in chamber slides and immuno-
stained with CD14, CD90, CD3 antibody (Santa Cruz
Biotechnology Inc) for 1 hour at room temperature prior to
incubation with fluorochrome-tagged secondary antibody
for 1 hour at room temperature. Counterstaining was
performed with DAPI to visualize nuclei. Fluorescent
microscopy was performed using a Nikon Eclipse TE2000-S
Microscope (Nikon, Tokyo, Japan) equipped with a Spot
Xplorer Leica digital camera (SPOT, Sterling Heights,
MI, USA).
Real-time quantitative PCR
For real-time PCR analysis, CD14+ selected macrophages
from ixmyelocel-T were compared to CD14+ monocytes
from the starting BMMNC population, M1 Macrophages,
or M2 Macrophages. Total RNA was extracted with the
RNeasy Mini Kit (Qiagen, Valencia, CA, USA) and 1 μg of
RNA was reverse transcribed using a high capacity cDNA
reverse transcription kit per the manufacturer’s directions
(Applied Biosciences, Carlsbad, CA, USA). Relative levels
of target gene expression were measured on the 7500
Real-Time PCR system (Applied Biosystems). FAM-based
Taqman Gene Expression Assay Mix (Applied Biosystems)
specific for each gene of interest and Taqman Universal
Master Mix (Applied Biosystems) were used. Relative
quantification PCR analysis was performed using the ABI
7500 Software (Applied Biosystems). The relative amount
of cDNA was calculated by normalization to the relative
levels of Gapdh.
Cytokine analysis
Enzyme-linked immunosorbent assay (ELISA) kits were
used to determine the concentrations of the following
cytokines: interleukin (IL)-10, IL-1ra, tumor necrosis factor
alpha (TNFα), and IL-12 p70 (R&D Systems, Minneapolis,
MN, USA). For cytokine analysis of ixmyelocel-T vs.
BMMNCs, cells were plated in the presence or absence
of 0.1 μg/mL lipopolysaccharide (LPS) overnight. After
LPS challenge, supernatants were collected and assayed
for cytokines. For cytokine analysis of ixmyelocel-T mac-
rophages vs. M1/M2 macrophages, cells were positively
selected using CD14 MACS beads (Miltenyi Biotech) to
isolate macrophages. After selection, cells were plated in
the presence or absence of 0.1 μg/mL lipopolysaccharide
(LPS) overnight. After LPS challenge, supernatants were
collected and assayed for cytokines.
Efferocytosis assay
BMMNCs were cryopreserved for use in the efferocytosis
experiments. Frozen BMMNCs were thawed, washed,
and then labeled with the lipophilic dye PKH26 as recom-
mended by the manufacturer (Sigma, St. Louis, MO, USA),and apoptosis was induced with 2 μM staurosporine
(Sigma). The apoptotic PKH26-labeled BMMNCs were
added in a 1:1 concentration to ixmyelocel-T derived
from the same marrow donor. For fluorescent microscopy,
ixmyelocel-T was labeled with PKH67 as recommended
by the manufacturer (Sigma). Ixmyelocel-T was incubated
with the apoptotic PKH26-labeled BMMNCs for 3 hours
and then washed with PBS. The ixmyelocel-T samples
mixed with apoptotic cells were then analyzed by fluores-
cent microscopy to determine if ixmyelocel-T macrophages
ingested apoptotic cells.
Statistical analysis
Paired t-test was performed to compare results. A p-value
less than 0.05 was considered statistically significant. Data
are reported as mean ± SEM.
Results
Ixmyelocel-T contains a population of M2-like
macrophages
Ixmyelocel-T is composed of a mixture of cells, specifically
this mixture contains myeloid cells (macrophages, granu-
locytes, monocytes, and mixed myeloid progenitors),
lymphoid cells (T cells, B cells, and a mixture of lymphoid
precursors) and MSC/stromal cells [20]. As reported pre-
viously, the two main cell types expanded from BMMNCs
in Aastrom’s manufacturing process are CD90+ stromal
cells and CD14+ macrophages [20]. On average there is
about a 90 fold increase in CD14+ macrophages in
ixmyelocel-T from BMMNCs [20]. Figure 1 displays a
microscopy image of ixmyelocel-T, and highlights the two
populations which are expanded in this culture process
(Figure 1).
This mixture of cells has previously been presumptively
defined as anti-inflammatory, with a majority of the anti-
inflammatory cytokines’ secretion being attributed to the
expanded population of CD14+ macrophages [20]. The
secretory cytokine profile of ixmyelocel-T macrophages
has previously been reported to be consistent with a
M2-like phenotype since it has been stated that M2
macrophages regulate the inflammatory response by pro-
ducing anti-inflammatory cytokines including IL-1ra and
IL-10 [7,20,26]. This mixed cellular therapy is injected into
disease states which are often associated with inflamma-
tion; therefore to determine if this anti-inflammatory
profile would remain in the face of inflammatory challenge,
the cells were stimulated with LPS overnight. These results
were compared to BMMNC to determine if this effect is
due to the ex vivo expansion of the cells. Ixmyelocel-T
secreted significantly elevated levels of the anti-inflammatory
cytokine IL-10 before (583 ± 154 vs 5 ± 2 pg/ml, p < 0.01
compared with BMMNCs, Figure 2A) and after (391 ± 11
vs 1547 ± 173 pg/ml, p < 0.001 compared with BMMNCs,
Figure 2A) LPS stimulation compared to BMMNCs.
Figure 1 Ixmyelocel-T contains a mixture of cells, mainly expanded CD14+ macrophages and CD90+ MSC. (A) Phase imaging depicts the
mixture of cells found in ixmyelocel-T. (B) Fluorescent imaging of CD90 (purple), CD14 (green), CD3 (red), and nuclei. Magnification: 20 ×.
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levels of the anti-inflammatory cytokine IL-1ra before
(4207 ± 934 vs 562 ± 68 pg/ml, p < 0.01 compared with
BMMNCs, Figure 2B) and after (15685 ± 2656 vs 1898 ±
81 pg/ml, p < 0.001 compared with BMMNCs, Figure 2B)
LPS stimulation compared to BMMNCs. Both ixmyelocel-T
and BMMNCs secreted low levels of the pro-inflammatory
cytokine TNFα before LPS stimulation (27 ± 11 vs 9 ±
1 pg/ml, p = 0.17 compared with BMMNCs, Figure 2C).
Ixmyelocel-T secretion of TNFα remained low after LPS
stimulation in comparison to BMMNCs (158 ± 52 vs
2872 ± 141 pg/ml, p < 0.001 compared with BMMNCs,
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Figure 2 The expansion process used to produce ixmyelocel-T results
TNFα, (D) IL-12 were quantified in BMMNCs and ixmyelocel-T supernatants
presented as mean ± SEM relative to control, *P <0.01, **P <0.001 vs BMMN
LPS, lipopolysaccharide; SEM = standard error of the mean.and BMMNCs secreted low levels of the pro-inflammatory
cytokine IL-12 p70 before LPS stimulation (5 ± 2 vs 8 ±
2 pg/ml, p = 0.21 compared with BMMNCs, Figure 2D).
Ixmyelocel-T secretion of IL-12 remained low after LPS
stimulation in comparison to BMMNCs (7 ± 5 vs 18 ±
3 pg/ml, p = 0.07 compared with BMMNCs, Figure 2D)
compared to BMMNCs. These results suggest that the
expansion process used to generate ixmyelocel-T from
BMMNCs generates this anti-inflammatory phenotype.
Consistent with previously reported findings, quantitative
real-time PCR analysis demonstrated that the process
used to generate ixmyelocel-T macrophages results in in-
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in an anti-inflammatory cytokine profile. (A) IL-10, (B) IL-r1a, (C)
treated with and without 0.1 μg/mL LPS (n = 5–11). Values are
C + LPS. #P <0.01, ##P <0.001 vs IXT + LPS. &P <0.01 vs BMMNC -LPS.
Ledford et al. Stem Cell Research & Therapy 2013, 4:134 Page 5 of 13
http://stemcellres.com/content/4/6/134ixmyelocel-T macrophages express a statistically signifi-
cantly higher level of 3 scavenger receptors that are
reported to be expressed on M2 macrophages [5,27]:
the mannose receptor (CD206) (1856 ± 730 vs 1 ± 0.65
relative expression, p < 0.05 compared with BMMNCs;
Figure 3A), the haptoglobin-hemoglobin scavenger receptor
(CD163) (97 ± 9.26 vs 1 ± 0.54 relative expression, p < 0.001
compared with BMMNCs; Figure 3B), and scavenger
receptor (SR)-B1 (16 ± 2.88 vs 1 ± 0.15 relative expression,
p < 0.001 compared with BMMNCs; Figure 3C). Ixmyelo-
cel-T macrophages were also found to express significantly
upregulated levels of MerTK (22 ± 4.98 vs 1 ± 0.43 relative
expression, p < 0.01 compared with BMMNCs; Figure 3D),
a receptor involved in the phagocytosis of apoptotic cells
[28,29]. These cells also expressed PPAR γ (27 ± 3.68 vs.
1 ± 0.58 relative expression, p < 0.001 compared with
BMMNCs; Figure 3E), a ligand-activated nuclear receptor
which is induced upon differentiation of monocytes into


































































































Figure 3 Ixmyelocel-T macrophages express genes of alternatively
gene expression analysis of alternatively activated macrophage marker
(n ≥ 4). Relative expression of (A) CD206, (B) CD163, (C) SR-B1, (D) Me
Values are presented as mean ± SEM relative to control, *P <0.05 vs ixm
GAPDH, glyceraldehyde 3-phosphate dehydrogenase; PPAR-γ, peroxiso
growth factor beta.factor (TGF)-β, an indicator of the anti-inflammatory
phenotype, was also increased in ixmyelocel-T macrophages
(21 ± 6.69 vs 1 ± 0.85 relative expression, p < 0.01 compared
with BMMNCs; Figure 3F) [31,32]. Together these findings
suggest that ex vivo expansion produces a CD14+ popula-
tion of cells with an M2-like phenotype.
Flow cytometry analysis (Figure 4A) confirmed that
ixmyelocel-T macrophages express 2 well-known surface
receptors of M2 macrophages: CD206 and CD163 [33].
On average 17% of the cells in ixmyelocel-T express
CD206 (17 ± 0.6%) and 15% of the cells in ixmyelocel-T
express CD163 (15 ± 1.3%). Since ixmyelocel-T consists
of a mixture of cells two markers of pro-inflammatory
macrophages were also examined. Flow cytometry analysis
revealed that the expression of the two pro-inflammatory
markers associated withM1macrophages- CD16 (Figure 5A)
and HLA-DR (Figure 5B) is minimal on ixmyelocel-T
macrophages. These findings suggest that ixmyelocel-T


















































activated macrophage phenotype. Quantitative real-time PCR
s within the ixmyelocel-T macrophages normalized to GAPDH
rTK, (E) PPARγ, and (F) TGFβ in CD14+ ixmyelocel-T macrophages.
yelocel-T, **P < 0.01 vs ixmyelocel-T, ***P < 0.001 vs ixmyelocel-T.

















Figure 4 Ixmyelocel-T macrophages express M2 macrophage surface receptors. (A) Ixmyelocel-T stained with the M2 macrophage markers
CD163 and CD206.
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M2-like macrophage
Since ixmyelocel-T macrophages were found to primarily
express surface expression of M2 markers, ixmyelocel-T
macrophages were further characterized by direct com-
parison to M1 and M2 macrophages generated in vitro.





















Figure 5 Ixmyelocel-T macrophages do not express pro-inflammatory
stained with the markers (A) CD16 and (B) HLA-DR.ixmyelocel-T macrophages express several M2 Macrophage
markers. Ixmyelocel-T and M2 macrophages expressed
similar levels of PPARɣ- (1.0 ± 0.3 vs 1.1 ± 0.1 relative
expression, p = 0.42 compared with M2; Figure 6A). M2
macrophages expressed significantly higher levels of CD206
(1.0 ± 0.2 vs 2.4 ± 0.3 relative expression, p < 0.001 compared
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Figure 6 Ixmyelocel-T macrophages express M2 markers. Quantitative real-time PCR gene expression analysis of M1 and M2 macrophage
markers within the ixmyelocel-T, M1, and M2 macrophages normalized to GAPDH (n≥ 4). Relative expression of (A) PPARγ, (B) CD206, (C) CD163,
(D) CD204, (E) SR-B1, (F) MERTK, (G) CCR7, (H) TNFα, (I) IL-1β, and (J) TGFβ in M1, M2, and IXT macrophages. Values are presented as mean ± SEM
relative to IXT, *P <0.05, **P < 0.01, ***P < 0.001 vs M1, #P <0.05, ##P < 0.01, ###P < 0.001 vs M2. PPAR-γ, peroxisome proliferator-activated receptor
gamma; TGFβ, transforming growth factor beta.
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0.6 ± 0.1 relative expression, p < 0.01 compared with M2;
Figure 6C). Ixmyelocel-T macrophages expressed lower
levels of the scavenger receptors CD204 (1.0 ± 0.2 vs 2.6 ±
0.2 relative expression, p < 0.001 compared with M2;
Figure 6D) and SR-B1 (1.0 ± 0.4 vs 4.2 ± 0.6 relative expres-
sion, p < 0.001 compared with M2; Figure 6E) in comparison
to M2 macrophages, whereas ixmyelocel-T macrophagesexpressed significantly elevated levels of the scavenger
receptor MerTK (1.0 ± 0.1 vs 0.2 ± 0.03 relative expression,
p < 0.001 compared with M2; Figure 6F). M1 macrophages
expressed relatively low expression of all these markers,
consistent with previous reports [6,24,34]. Ixmyelocel-T
macrophages expressed significantly lower expression of
the M1 macrophage markers CCR7 (1.0 ± 0.4 vs 1058 ± 105
relative expression, p < 0.001 compared with M1; Figure 6G),
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compared with M1; Figure 6H), and IL-1β (1.0 ± 0.4 vs
14.8 ± 2.6 relative expression, p < 0.001 compared with M1;
Figure 6I). Additionally, ixmyelocel-T macrophages were
found to express elevated levels of the reparative cytokine
TGF-β (Figure 6J). These findings suggest that ixmyelocel-T
macrophages are mainly M2-like, as they share little
gene expression in common with M1 macrophages. These
finding also suggest that ixmyelocel-T macrophages have
a unique M2-like profile since they express lower levels of
the scavenger receptors CD204 and SR-B1, and elevated
expression of CD163 and MerTK.
M1 and M2 macrophage profiles are described as plastic,
with M2 macrophages reported to secrete elevated amounts
of the pro-inflammatory cytokines TNFα and IL-12 after
stimulation with LPS [26,33]. Since ixmyelocel-T was found
to secrete low levels of the pro-inflammatory cytokines
TNFα and IL-12 after inflammatory challenge, we chal-
lenged M1, M2 and ixmyelocel-T macrophages with LPS
overnight to determine the plasticity of their phenotype.
Basally, both M2 (29 ± 11 pg/mL; Figure 7A) and ixmyelo-
cel-T macrophages (116 ± 15 pg/mL; Figure 7A) secrete
minimal amounts of TNFα, whereas M1 macrophages
(14893 ± 2247 pg/mL; Figure 7A) secrete elevated levels of
TNFα. Ixmyelocel-T macrophages secrete significantly
higher levels of TNFα compared to M2 macrophages
(116 ± 15 vs 29 ± 11 pg/mL, p < 0.001 compared with M2;
Figure 7A). Ixmyelocel-T macrophages secrete lower levels
of TNFα compared to M1 macrophages (116 ± 15 vs
14893 ± 2247 pg/mL, p < 0.001 compared with M1;
Figure 7A). As reported previously [35], after stimulation
with LPS M2 macrophages secrete significantly elevated
levels of TNFα (15182 ± 718 vs 29 ± 11 pg/mL, p < 0.001
compared with M2 -LPS; Figure 7A). Ixmyelocel-T mac-
rophages also secrete significantly elevated levels of TNFα
after LPS stimulation (184 ± 27 vs 116 ± 15 pg/mL, p < 0.05
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Figure 7 Ixmyelocel-T macrophages remain anti-inflammatory after in
M1, M2, and ixmyelocel-T supernatants treated with and without 0.1 μg/m
*P <0.001 vs M1. #P <0.001 vs M2. &P <0.05 vs IXT. ^P <0.05, ^^P <0.001 vs M1
error of the mean.increase in secretion after LPS stimulation is significantly
lower in comparison to M1 (184 ± 27 vs 16342 ± 4200 pg/
mL, p < 0.001 compared with M1 + LPS; Figure 7A) and
M2 (184 ± 27 vs 15182 ± 718 pg/mL, p < 0.001 compared
with M2 + LPS; Figure 7A) macrophages. Basally, both M2
(9 ± 3 pg/mL; Figure 7B) and ixmyelocel-T (5 ± 2 pg/mL;
Figure 7B) macrophages secrete minimal amounts of
IL-12 p70, whereas M1 macrophages (129 ± 23 pg/mL;
Figure 7B) secrete elevated levels of IL-12 p70. As reported
previously, after stimulation with LPS M2 macrophages
secrete significantly elevated levels of IL-12 p70 (113 ± 19
vs 9 ± 3 pg/mL, p < 0.001 compared with M2 -LPS;
Figure 7B) [35]. Whereas, ixmyelocel-T macrophages se-
crete significantly lower amounts of IL-12 p70 after LPS
stimulation compared to both M1 (5 ± 2 vs 167 ± 21 pg/mL,
p < 0.001 compared with M1 + LPS; Figure 7B) and M2
(5 ± 2 vs 113 ± 19 pg/mL, p < 0.001 compared with M2 +
LPS; Figure 7B) macrophages. These data suggest that
ixmyelocel-T macrophages are not readily polarized to
a pro-inflammatory phenotype.
Ixmyelocel-T macrophages express MerTK, a receptor
involved in efferocytosis
M2 macrophages promote the resolution of inflammation
by scavenging apoptotic cells, an action termed effero-
cytosis. Flow cytometry analysis confirmed that ixmyelo-
cel-T macrophages express the surface receptor MerTK
(Figure 8A), a receptor involved in the phagocytosis of
apoptotic cells [28,29]. To investigate the ability of ixmyelo-
cel-T macrophages to phagocytize apoptotic cells, PKH26-
labeled apoptotic BMMNCs were added to ixmyelocel-T
in a 1:1 ratio, incubated at 37°C for 3 hours, and then
washed with PBS. Fluorescent microscopy and flow cytom-
etry revealed that ixmyelocel-T macrophages ingest apop-
totic cells (Figure 8B-C). On average 20% percent of
ixmyelocel-T CD14+ cells were positive for PKH26+
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flammatory challenge. (A) TNFα and (B) IL-12 were quantified in
L LPS (n = 4–7). Values are presented as mean ± SEM relative to control,
+ LPS. %P <0.001 vs M2 + LPS. LPS, lipopolysaccharide; SEM = standard
ixmyelocel-T Apoptotic Cells






























Figure 8 Ixmyelocel-T alternatively activated macrophages readily phagocytize apoptotic cells. (A) Ixmyelocel-T stained with MerTK.
(B-C) Adherent, healthy ixmyelocel-T stained with PKH67 was incubated with PKH26 labeled apoptotic cells. Apoptotic cells were washed away,
and healthy ixmyelocel macrophages were analyzed using fluorescence microscopy and flow cytometry. On average 20% percent of ixmyelocel-T
CD14+ cells were positive for PKH26+ apoptotic cells after a three hour co-culture apoptotic cells (20 ± 2.9%). (n≥ 5). Magnification: 60 ×.
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In this report, ixmyelocel-T was found to secrete signifi-
cantly elevated levels of both IL-10 and IL-1ra before
and after LPS stimulation, compared to BMMNCs. Add-
itionally, both ixmyelocel-T and BMMNCs were foundto secrete minimal amounts of the pro-inflammatory cy-
tokines TNFα and IL-12. After LPS challenge both
ixmyelocel-T and BMMNCs secreted significantly more
TNFα, however this increase in secretion was significantly
higher in BMMNCs. This expanded population of M2-like
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elevated levels of the M2 markers CD206, CD163, SR-B1,
MerTK, PPARɣ, and TGF-β. Together these findings
suggest that the 12 ± 1 day ex vivo expansion of autologous
marrow generates a population of M2-like macrophages in
ixmyelocel-T.
Ixmyelocel-T macrophages were demonstrated to express
2 well-characterized surface markers of M2 macrophages,
CD206 and CD163. Whereas surface expression of markers
of pro-inflammatory macrophages, CD16 and HLA-DR
[36,37], were found to be barely expressed. Studies have
demonstrated that macrophages with high expression of
CD16 efficiently produce pro-inflammatory cytokines
including TNFα and IL-12, while no or very little anti-
inflammatory cytokines, whereas macrophages with low
expression of CD16 produce low levels of pro-inflammatory
cytokines and secrete elevated levels of anti-inflammatory
cytokines such as IL-10 [37,38]. These findings suggest that
ixmyelocel-T consists mainly of macrophages with anti-
inflammatory M2-like phenotypes.
In vivo, bone marrow-derived macrophages differentiate
from circulating peripheral blood monocytes after migra-
tion into tissues, often in response to injury or insult.
These macrophages can then be polarized into M1 or M2
macrophages by their microenvironment [39]. As a cellular
therapy, ixmyelocel-T macrophages are generated ex vivo
from bone marrow and directly injected into areas where
repair is needed [20,22]. In order to further explore the
differences between these cell phenotypes ixmyelocel-T
macrophages were compared to M2 and M1 macrophages.
Both Ixmyelocel-T and M2 macrophages were found to
express similar levels of PPARɣ. Ixmyelocel-T macrophages
were found to express significantly lower levels of the
scavenger receptors CD206, CD204, and SR-B1 compared
to M2 macrophages. However, ixmyelocel-T macrophages
were found to express significantly higher expression of
the scavenger receptors CD163 and MerTK compared to
M2 macrophages. Ixmyelocel-T macrophages were also
found to have significantly higher expression of TGF-β
compared to M1 and M2 macrophages. When compared
to M1 macrophages both M2 and ixmyelocel-T macro-
phages were found to express significantly lower levels of
the M1 markers CCR7, TNFα, and IL-1β. Together these
data suggest that ixmyelocel-T macrophages are more
M2-like. This data also suggests that ixmyelocel-T macro-
phages may represent a unique M2-like macrophage, with
slightly different expression of M2 markers. Future studies
will further examine the unique M2- like phenotype of
ixmyelocel-T macrophages to determine just how similar
or different they are to M2 macrophages.
Macrophages are plastic cells that can switch from an
activated M1 state back to M2, and vice versa depending
on specific signals [26,33]. Previous reports have demon-
strated that M2 macrophages can be polarized back to aM1 state using pro-inflammatory stimuli such as LPS [35].
To determine if ixmyelocel-T macrophages could also be
polarized back to a M1 state in a similar fashion M1, M2,
and ixmyelocel-T macrophages were treated with LPS over-
night. Before LPS stimulation both M2 and ixmyelocel-T
macrophages secreted significantly less TNFα and IL-12
p70 compared to M1 macrophages. However after over-
night LPS stimulation, M2 macrophages secreted signifi-
cantly elevated levels of TNFα and IL-12 p70 similar to
M1 levels. This same amount of pro-inflammatory cytokine
secretion was not mimicked by ixmyelocel-T macrophages.
While ixmyelocel-T macrophages did secrete significantly
elevated levels of TNFα after LPS stimulation, this amount
of TNFα was significantly lower than that secreted by M2
macrophages. Additionally, ixmyelocel-T macrophages se-
creted significantly less IL-12 p70 after LPS stimulation
compared to M1 and M2 macrophages. These data suggest
that ixmyelocel-T macrophages are not readily polarized to
a pro-inflammatory phenotype, suggesting that these
cells might be beneficial in the treatment of inflammatory
diseases. Future studies will further investigate this unique
property of ixmyelocel-T macrophages to determine if
they can affect the inflammatory state in vivo.
M2 macrophages are potent phagocytes that favorably
bind and ingest early apoptotic cells [40]. Apoptotic cells
need to be removed quickly to prevent the release of
tissue-damaging intracellular components that can induce
inflammatory responses [28,41]. Efferocytosis itself also
triggers pro-resolving signals that promote dampening
of the immune response and restoring tissue homeostasis
[14]. Defective clearance of apoptotic cells, or efferocytosis,
is linked to the progression of several disease states includ-
ing advanced atherosclerotic lesions, ischemic heart disease,
and chronic wounds [28]. Ixmyelocel-T macrophages were
found to readily ingest apoptotic cells and express genes for
the scavenger receptors that promote the phagocytosis of
apoptotic cells. Of specific interest, ixmyelocel-T expresses
the scavenger receptor MerTK, which has been implicated
in mediating the anti-inflammatory clearance of apoptotic
cells [29,42]. The expression of scavenger receptors and
their M2-like phenotype predisposes ixmyelocel-T macro-
phages to be potent phagocytes. This important function
of ixmyelocel-T macrophages could potentially promote
healing in disease states where efferocytosis is compro-
mised. Specifically, advanced atherosclerotic lesions are
characterized by defective efferocytosis, resulting in nec-
rotic core formation [28,42]. In early atherosclerotic lesions,
apoptotic cells are rapidly removed by macrophages, which
prevents the progression of lesions, but as the disease
progresses, apoptotic cells are not removed, resulting in a
pro-inflammatory cascade [28]. Efferocytosis is also required
in healing the heart after ischemia where removing necrotic
debris helps preserve the remaining cardiomyocytes [14].
As such, the macrophages present in ixmyelocel-T may
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the removal of necrotic debris.
Several different mechanisms have been reported in
the literature that may contribute to the development of
M2 macrophages, including ingestion of apoptotic cells,
exposure to the Th2 cytokines IL-4 and IL-13, exposure
to IL-10, and contact with mesenchymal stem cells
[13,27,39,43]. The culture process used to generate
ixmyelocel-T results in a population of unique M2-like
macrophages. Th2 cytokines are not directly added to
ixmyelocel-T during the culture process to produce
M2 macrophages [1,31,44]. However, due to the wide
mixture of cells found within ixmyelocel-T it is feasible
that Th2 cytokines may be generated and secreted by
other cells during this 12 ± 1 day process. Ixmyelocel-T
is composed of a mixture of cells including macrophages,
granulocytes, monocytes, T cells, B cells, and MSC/stro-
mal cells, and cytokine secretion from these different cell
types could influence the development of the M2-like
phenotype [20]. For example, it has been previously
reported that macrophages engage in bidirectional interac-
tions with MSCs, resulting in MSC growth and M2
phenotype polarization [7,12,45]. MSCs have been reported
to induce an IL-10 high and IL-12 low M2 phenotype
in macrophages [39]. MSCs are expanded during the
ixmyelocel-T culture process; the interaction of these
cells with macrophages in culture could contribute to the
M2-like population of cells found within ixmyelocel-T.
Future studies will further examine the relationship be-
tween these different cell types to determine if they
play a role in the development of this M2-like population
of macrophages.
Ixmyelocel-T is currently being evaluated in a Phase 2b
clinical trial of advanced heart failure. Tissue recovery after
injury is a complex process involving an interplay between
macrophages, stem cells, and stromal cells to prevent tissue
fibrosis, which can lead to ineffective tissue function [7].
Recent work has highlighted the role of M2 macrophages
in these processes [7,17,46]. Macrophages are commonly
found in association with areas of fibrosis in cardiac tissue
in end-stage heart disease [9], and recent studies have
provided evidence that M2-like macrophages have the
capacity to remove tissue debris and dampen inflammation
in cardiac tissue promoting tissue repair [8]. Additionally,
recent studies have found that macrophages found in
human carotid artery atherosclerotic plaques are dominated
by a M1 phenotype [47], and that the number of pro-
inflammatory M1 macrophages found in cardiac adipose
tissue correlates with the severity of coronary artery ath-
erosclerosis in human [12]. Therefore, ixmyelocel-T may
potentially promote tissue repair and regeneration in these
disease states by providing a M2-like population of macro-
phages described herein. The biological properties of these
macrophages in ixmyelocel-T may potentially have clinicalutility for tissue repair and regeneration in the disease
states where a population of M2 macrophages would be
critical.
This study further examined the expanded population
of macrophages found in ixmyelocel-T, since macrophages
have been reported to play specific and unique roles in
tissue regeneration and repair [7,17,46]. Several cellular
therapies are currently being explored for the treatment of
ischemic cardiovascular diseases where tissue remodeling
and immunomodulation are considered key components
of successful clinical outcomes. BMMNCs, peripheral blood
mononuclear cells, endothelial progenitor cells (EPC), and
MSCs are all currently being evaluated in the treatment of
ischemic cardiovascular diseases [48]. Tissue regeneration
is a complex process involving an interplay between mac-
rophages, stem cells, and stromal cells to prevent tissue
fibrosis, which can lead to ineffective tissue function, and
it is hypothesized that a mixture of regenerative cells, rather
than just a single cell type might be more advantageous
[7,20,48,49]. Ixmyelocel-T consists of a mixture of cells
generated from BMMNCs, specifically an expanded
population of CD90+ stromal cells and CD14+ macro-
phages which have been characterized with a M2-like
phenotype [20]. It is thought that the mixture of cells found
in ixmyelocel-T might be more advantageous in long-term
tissue regeneration and repair [20,48]. Future studies will
further characterize the other cells types that make up
ixmyelocel-T in order to highlight the potential roles these
other subpopulations might play in tissue repair and
regeneration.
There are several limitations to this study. Mainly, the
findings and conclusions are based on in vitro experiments.
The outcome of infiltrating macrophages to areas of inflam-
matory injury is not fully understood as the inflammatory
environment may influence the outcome of the cells.
Although we used human cells that would require the use
of immune-compromised animals, in vivo experiments
would strengthen the findings. Additionally, the cells in
these experiments were obtained from healthy donors.
It would be highly interesting to compare ixmyelocel-T
macrophages to the peripheral blood macrophages (polar-
ized M1 and M2) from a diseased patient. Studies have re-
ported that several disease states, such as obesity and type
2 diabetes, affect macrophage phenotype and polarization
in some cases limiting M2 polarization capacity [26,50].
Therefore, it would useful to compare ixmyelocel-T
macrophages to peripheral blood macrophages in clinically
relevant states; especially disease states where ixmyelocel-T
is injected as a treatment.
Conclusion
Our data demonstrate that ixmyelocel-T therapy contains
a unique population of M2-like macrophages that are
characterized by secretion of anti-inflammatory cytokines
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Furthermore, these cells are involved in efficient removal
of apoptotic cells and have elevated expression of MerTK,
which is imperative in limiting tissue injury and promoting
repair. The biological properties of the M2-like macro-
phages in ixmyelocel-T may have clinical utility for tissue
repair and regeneration in the disease states where a popu-
lation of M2 macrophages would be critical.
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